title: Cell-based regenerative strategies for treatment of diabetic skin wounds, a comparative study between human umbilical cord blood-mononuclear cells and calves' blood haemodialysate.
abstract: BACKGROUND
  Diabetes-related foot problems are bound to increase. However, medical therapies for wound care are limited; therefore, the need for development of new treatment modalities to improve wound healing in diabetic patients is essential and constitutes an emerging field of investigation.
  
  
  METHODS
  Animals were randomly divided into 8 groups (I-VIII) (32 rats/group), all were streptozotocin (STZ)-induced diabetics except groups III and VIII were non-diabetic controls. The study comprised two experiments; the first included 3 groups. Group I injected with mononuclear cells (MNCs) derived from human umbilical cord blood (HUCB), group II a diabetic control group (PBS i.v). The second experiment included 5 groups, groups IV, V, and VI received topical HUCB-haemodialysate (HD), calves' blood HD, and solcoseryl, respectively. Group VII was the diabetic control group (topical saline). Standard circular wounds were created on the back of rats. A sample of each type of HD was analyzed using the high performance liquid chromatography-electrospray ionization-mass spectrometry (HPLC-ESI-MS) system. Wound area measurement and photography were carried out every 4 days. Plasma glucose, catalase (CAT), malondialdehyde (MDA), nitric oxide (NO) and platelets count were assessed. Wound samples were excised for hydroxyproline (HP) and histopathological study.
  
  
  RESULTS
  Treatment with HUCB MNCs or HUCB-HD resulted in wound contraction, increased CAT, NO, platelets count, body weights, and HP content, and decreased MDA and glucose.
  
  
  CONCLUSIONS
  Systemic administration of HUCB MNCs and topical application of the newly prepared HUCB-HD or calves' blood HD significantly accelerated the rate of diabetic wound healing and would open the possibility of their future use in regenerative medicine.
authors.affiliation: Biochemistry Department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.
authors.forename: Hala O
authors.initials: HO
authors.lastname: El-Mesallamy
authors.affiliation: Research Department, Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.
authors.forename: Mohamed R
authors.initials: MR
authors.lastname: Diab
authors.affiliation: Biochemistry Department, Faculty of Pharmacy, Ain-Shams University, Cairo, Egypt.
authors.forename: Nadia M
authors.initials: NM
authors.lastname: Hamdy
authors.affiliation: Research Department, Holding Company for Biological Products and Vaccines (VACSERA), Giza, Egypt.
authors.forename: Sarah M
authors.initials: SM
authors.lastname: Dardir
mesh_terms: D000183:Actihaemyl / Q000494:pharmacology; D000818:Animals; D001786:Blood Glucose / Q000378:metabolism; D001792:Blood Platelets / Q000187:drug effects; D002374:Catalase / Q000097:blood; D002417:Cattle; D003921:Diabetes Mellitus, Experimental / Q000097:blood / Q000503:physiopathology*; D005260:Female; D005312:Fetal Blood / Q000737:chemistry / Q000166:cytology; D015312:Hemodialysis Solutions / Q000494:pharmacology*; D006801:Humans; D007963:Leukocytes, Mononuclear / Q000166:cytology / Q000637:transplantation*; D008297:Male; D008315:Malondialdehyde / Q000097:blood; D009569:Nitric Oxide / Q000097:blood; D051381:Rats; D017208:Rats, Wistar; D012867:Skin / Q000187:drug effects* / Q000293:injuries / Q000503:physiopathology; D014020:Tissue Extracts / Q000494:pharmacology; D014945:Wound Healing / Q000187:drug effects*
chemical_list: D001786:Blood Glucose; D015312:Hemodialysis Solutions; D014020:Tissue Extracts; D009569:Nitric Oxide; D000183:Actihaemyl; D008315:Malondialdehyde; D002374:Catalase